论文部分内容阅读
辉瑞公司开发的单剂量阿奇霉素微球剂已向美国申请用于治疗成人呼吸道感染,包括慢性支气管炎急性细菌性感染(AECB)、急性细菌性鼻窦炎(ABS)和社区获得性肺炎 (CAP)。该制剂具有长效,单剂量2 g在小肠内缓慢完全释放。公司称患者对其顺应性为100％,应在细菌感染最严重的早期服用。在2004年11月中旬华盛顿举行的国际抗生素与化疗学会(ICAAC)上,公司发表了阿奇霉素微球剂与常用制剂进行比较的三个关键试验的数据。结果表明,单剂量
A single dose azithromycin microspheres developed by Pfizer has been filed in the United States for the treatment of adult respiratory infections, including acute bacterial infections of chronic bronchitis (AECB), acute bacterial sinusitis (ABS) and community acquired pneumonia (CAP). The formulation has long-lasting effects, with a single dose of 2 g slowly and completely released in the small intestine. The company claims that patients are 100% compliant and should be taken early in the most severe bacterial infections. At the International Society for Antibiotics and Chemotherapy (ICAAC) in mid-November 2004 in Washington, DC, the company published data on three key trials comparing azithromycin microspheres with commonly used formulations. The results show that single dose